Home » Topics » BioWorld Science

BioWorld Science
RSS

Cancer therapy driven by dopamine D2 receptor antagonism shows promise

May 7, 2018

Novel oral antibiotic DDS-01 presented for treating multidrug-resistant gonorrhoea infections

May 7, 2018

Astellas reports pipeline highlights of fourth quarter of fiscal 2017

May 7, 2018

DSMB gives another recommendation for phase III FOCUS trial

May 7, 2018

GAL-200-10 controls corneal neovascularization and fibrosis in vivo

May 7, 2018

FDA grants fast track designation for PaxVax's chikungunya VLP vaccine

May 7, 2018

MenoGeniX receives grant from NIA for drug to treat menopausal hot flashes

May 7, 2018

Sarepta partners with Myonexus to advance gene therapies for limb-girdle muscular dystrophy

May 4, 2018

EMA validates type II variation application for Opdivo plus Yervoy in first-line NSCLC

May 4, 2018

OTL-200 receives rare pediatric disease designation from the FDA

May 4, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...